Full-Year 2020 results

March 18, 2021





INVESTING FOR THE LONG TERM



Demonstrated portfolio resilience during an unprecedented crisis

Preserved intrinsic shareholder value & potential value creation opportunities

Emphasized Engagement & ESG

Able to capitalize on solid financial structure, €1.8bn liquidity and modest overall leverage at Wendel and portfolio levels

Wendel and its portfolio companies are well positioned to seize opportunities

— 2020: A tale of two halves

H1: Covid 19 outbreak / Global lockdown of major economies

Focused on preserving value against precipitous declines in revenues and profits at many companies:

- Kept people safe
- Planned and secured liquidity for companies and enhanced Wendel's financial resources
- Preserved long term levers of improvement: Digital, R&D, ESG, Compliance

No equity injections in our companies required

H2: Gradual end of lockdowns / Managed reopenings

Moved towards the rebound phase from Q3:

- Portfolio companies taking advantage of relative competitive strength
- Resuming investment activity at Wendel and at portfolio companies
- Improved non-financial ratings

Paid a stable dividend to Wendel shareholders Seeking new assets: 2 fully financed offers made over the last 3 months

NAV 166.3 -16.7% 138.6 +14.8% 159.1

€ per share +16.8%

WENDE

161.9

— 2020 key highlights

Wendel

Full disposal of Allied Universal and Tsebo

Wendel office footprint rightsized

Wendel Lab: additional capital committed to top quality funds

ESG acceleration and extra-financial ratings improved

Dividend maintained

Executive Board reappointed

Portfolio

COVID-19 crisis: all companies exceeded reforecasts prepared in March

Cromology turn-around well underway

Pim Vervaat appointed CEO of Constantia

IHS: successful amendment of contract terms with MTN Nigeria

— Full-Year 2020 key figures: Good financial performance



NAV: €159.1 per share, down only 4.3% YoY (as of December 31, 2020)

Consolidated sales of €7.5bn, **down 8.0% overall** of which **-5.4% organically**

Consolidated net loss of €231m (€264m Group share)



Proposed dividend for 2020 of €2.9 per share, up 3.6%

Preserved solid financial structure and strong liquidity

Total liquidity of €1.8bn





Corporate cash balance: €1.08 billion



€750m RCF available, fully undrawn



Solid dual credit ratings: BBB & Baa2



Long debt tenure: 4.5 years, no maturity before 2023

As of December 31, 2020

Major improvements in extra-financial ratings and distinctions in 2020

Extra-financial ratings 2020











69/100

2019: 1st assessment with a

58 score 2020: Inclusion in DJSI World and DJSI Europe with a 71 score

Member of

Sustainability Indices

Powered by the S&P Global CSA

Dow Jones



AA score (sectoral leader) Low Risk Ranked #1 among peers of similar market cap



1st assessment in 2020









Gender diversity and Transparency

Placed 24th in the SBF120 Women in Leadership rankings Ranked 4th most transparent company of the SBF120 index at the 2020 Labrador Grand Prix de la Transparence (Top 3 for Chart of Ethics)

We intend to disclose ESG information in compliance with leading reporting standards





As a publicly-listed company, Wendel and its controlled companies publish an annual Extra-Financial Performance Declaration (EFPD), audited by an independent third-party Wendel's EFPD complies with the Grenelle 2 Law, a French transposition of the GRI reporting standards



Currently reporting on contribution on the UN SDGs

+ Voluntary PRI reporting in 2021 and climate-risk disclosure following TCFD standards



Our ESG Risk Matrix follows the SASB recommendations for the financial sector



In March 2021, Wendel adopted the 10 Principles of the United Nations Global Compact.



We remain attentive to the future implementation of the EU green taxonomy

— NAV discount remains high vs. historical data


A high discount despite:

Comparably lower leverage at Wendel SE and portfolio levels

An overall financially resilient and refocused portfolio

Stable dividend payment in spite of the COVID crisis, implying a c.3.0% yield

Sizeable cash resources for new investments



Performance of Group companies FY 2020

Figures **include** IFRS 16, unless otherwise specified







- COVID-19 crisis managed successfully:

- Q
- Bureau Veritas posted resilient performance with dynamic rebound in H2
- Stahl protected its margins and cash, thanks to strong cost management
- Constantia Flexibles maintained its activity level & improved its profitability, despite harsh environment in key emerging countries/consumer businesses
- IHS Towers delivered good organic growth & successfully amended its contract with MTN Nigeria
- Cromology posted a remarkable recovery since lockdown with a return to organic growth in H2 and significant profitability improvements
- CPI developed distance learning programs to adapt to the challenging lockdown situation and benefits from a progressive recovery

Bureau Veritas





- Revenues of €4.6bn, down 9.8% year-on-year,
- Organic growth reached -6.0%, and -2.0% in Q4
 - Marine & Offshore delivered organic growth of +2.2%
 - Agri-Food & Commodities, Buildings & Infrastructure, Certification and Industry showed a good level of resistance overall, down 5.1% organically on average.
 - Consumer Products declined sharply due the impact of COVID-19 shutdowns, down
 15.0% organically on average
- Successful deployment of "Restart Your Business with BV"
- Launch of "BV Green Line" to support organizations executing their sustainability strategies
- Adjusted operating margin down -294bps to 13.4%⁽¹⁾
- Strong free cash flow thanks to optimization measures +2.6%
- Net debt / EBITDA ratio reduced YoY from 1.87x to $1.80x^{(2)}$
- Reinstated and proposing dividend in 2021: €0.36 per share⁽³⁾ payable in cash
- Acquisition projects were initially put on hold in 2020; M&A activity resumed more recently with the acquisition of Secura B.V.

2021 outlook disclosed by Bureau Veritas in February

The Group remains uniquely positioned thanks to the diversity and resilience of its portfolio and its numerous growth opportunities. Based on the current uncertainties around the Covid-19 pandemic and assuming no severe lockdowns in its main countries of operation, Bureau Veritas expects for the full year 2021 to:

- Achieve solid organic revenue growth;
- Improve the adjusted operating margin;
- Generate sustained strong cash flow

Bureau Veritas will unveil its strategic plan for the next 4 years in Q4 2021. It already presented its strategy for social and environmental responsibility up to 2025 with its annual results.



Including IFRS 16.

⁽²⁾ Adjusted net financial debt / EBITDA adjusted for all businesses acquired over the past 12 months, as defined for the Group's covenants calculation. Covenants' calculation defined contractually and excluding IFRS 16

⁽³⁾ Proposed dividend, subject to Shareholders' Meeting approval on June 25, 2021

COVID 19 crisis managed successfully :





Bureau Veritas posted resilient performance with dynamic rebound in H2

- **Stahl** protected its margins and cash, thanks to strong cost management
- Constantia Flexibles maintained its activity level & improved its profitability, despite harsh environment in key emerging countries/consumer businesses
- IHS Towers delivered good organic growth & successfully amended its contract with MTN Nigeria
- Cromology posted a remarkable recovery since lockdown with a return to organic growth in H2 and significant profitability improvements
- **CPI** developed distance learning programs to adapt to the challenging lockdown situation and benefits from a progressive recovery.


— Monthly sales analysis: impact of COVID-19 on our consolidated unlisted companies








Crisis Prevention Institute





IHS Towers





Total growth of +14.0% ⁽¹⁾ reflecting the critical nature of IHS activity despite challenging global macro environment

- +16.3% organic growth driven by new tenancies, new lease amendments), price escalation mechanisms as well as the positive impact of reset mechanisms related to the devaluation of Nigeria's CBN rate
- Total number of owned & MLL towers up 15.5% over the year (27,807 (3) as of 31 December 2020, following the acquisitions of Kuwait towers and CSS in South America)
- Consolidation of Kuwait towers and CSS in Q1 contributed positively to revenue growth, (+4.0%). FX rate changes had a negative impact of -6.4% over total revenues

Successful amendment of certain terms of its tower lease agreements with MTN Nigeria

- On July 23, 2020, IHS concluded an expansion and amendment of some key terms of its tower lease agreement with MTN Nigeria, its largest customer in the region. Amongst these: change of the reference rate from the Central Bank of Nigeria's official rate ("CBN"), to the Nigerian Autonomous Foreign Exchange rate ("NAFEX").
- This amendment had a positive impact on IHS's top and bottom line

EBIT⁽²⁾ margin at 29.2%

EBIT up 44.4% Y-o-Y in spite of depreciation catch up following change in battery useful life from 5 to 3 years. EBITDA is also up year-on-year

Net debt⁽⁴⁾ at \$1,932m, up \$591 million since start of the year resulting from external growth (Zain Kuwait & CSS), partly compensated by good cash flow generation

COVID-19 update:

- IHS supply chain and operations have proven to be resilient to the lockdown
- Macroeconomic environment in Nigeria, has been impacted by the drop in oil prices resulting in official CBN rate moving from 306 to 380 NGN for 1 USD and NAFEX from c360 to c.410 which is beneficial for IHS
- Focus on hard currency liquidity (in an environment of varying access to USD)



⁽¹⁾ Sales, growth, tower count and lease-up rate include the contribution of the c.1,000 towers transferred to IHS in February 2020 following the Kuwait deal (approximately 600 additional towers remain to be transferred to IHS early 2021) and the contribution of the CSS towers in Latin America included from Q2 2020


EBIT is excluding non-recurring items and including IFRS 16, excluding IFRS 16 EBIT is \$395.7m 2020

Tower count excluding managed services and WIP

After IFRS16

Stahl





Sales down 17.2% (-14.3% organic, -2.9% FX) impacted by COVID-19 mostly in Q2, with return to organic growth in Q4.

- Stahl began 2020 with positive volume and sales trends. In Q1, limited impact of COVID-19 outbreak, mainly in China, resulted in a contained sales drop of -2.4%.
- Q2 global lockdown rapidly forced many of Stahl's customers to shut down production facilities or operate at very low level of activity (despite most Stahl facilities remaining open).
 Sales down -45% in Q2 YoY.
- Gradual recovery since Q3, with return to positive organic growth in Q4 (+3.6% YoY)

Margin protected through strict cost management

- \sim 22.7% ⁽¹⁾, slightly up year-on-year.
- Despite this challenging context and thanks to management focus and solid business model, Stahl quickly adjusted its fixed cost base to market conditions and successfully optimized its cash flow generation.

Improvement of net debt to EBITDA ratio to 1.6x EBITDA (vs 2.0x end of 2019), benefiting from good cash conversion

- Net debt⁽²⁾ down €119.4m since the start of the year, to €245.0m thanks to Stahl's good cash generation, generating simultaneous reduction of gross debt and increase of cash available.
- Successful Amend and Extent of debt, extending maturities until 2023.

COVID-19 update:

- Stahl is closely monitoring the evolution of its underlying markets (automotive, footwear, leather goods, upholstery) which have all rebounded in H2 2020.
- Orderbook is currently at a healthy level. Quicker-than-expected recovery generates demand and supply chain tensions on certain products.

Maarten Heijbroek appointed new CEO for Stahl starting July 1st, 2021




⁽¹⁾ EBITDA including IFRS 16 impacts, EBITDA excluding IFRS 16 stands at €149.1m

⁽²⁾ Net debt including IFRS 16 impacts, net debt excluding IFRS 16 stood at €228.8m

Constantia Flexibles





Resilient activity in 2020 (-0.4% organically YoY), with a good performance in Europe, emerging countries being impacted by lockdowns (-1,9% total growth, +0.4% scope effect, -1.9% FX)

- Very robust performance from the Pharma end market, up +6.3 % but decline in the Consumer end market (-2.4%)mainly due mainly to lockdown's measures in India, South Africa and Mexico as well as lower demand in certain segments such as chewing gum
- These local trends were not offset by the peak in consumption from the European consumer business which benefitted from an increase in at-home food consumption.

Adjusted EBITDA up 1.8%(1)

- Margin of 12.6% (+50bps YoY)
- Increase driven by the various cost reduction initiatives conducted over the past 12 months, a positive business/regional mix and favorable raw material cost fluctuations

Strong cash flow generation amidst the Covid crisis: leverage @ 1.8x EBITDA(3)

- Continued improvement in working capital management
- Adequate headroom to covenant level of 3.75x, and the company had ample liquidity as of end of December

Covid-19 update:

From a peak in activity level in March and April 2020, due to the essential nature of Constantia's products within the context of COVID-19 outbreak, the overall business has remained resilient. This resilience is expected to continue over the course of 2021 although there are still some lingering effects of lower demand in certain product categories. There is also a much less favorable raw materials' prices' environment in 2021

- A new strategy called Vision 2025 is currently under preparation by the new management team
- This strategic roadmap should refocus strategic priorities primarily aiming to boost growth and profitability.
- The EcoLam sustainable technology, with superior recyclability than alternatives, has seen its deployment constrained by the COVID-19 crisis due to the difficulty of conducting trials. Sales should grow in 2021 subject to further disruption from the COVID-19 epidemic

⁾ EBITDA including IFRS 16 impacts and restated from Covid related costs for €6.1m. EBITDA including these costs stands at €183.3m. EBITDA before IFRS 16 and excl. Covid related costs stands at €180.9.




⁽³⁾ Leverage as per credit documentation, excluding IFRS 16



Cromology





Revenue down -6.0% in 2020 due to extreme lockdown conditions in March-April in Europe, followed by a strong rebound in activity since mid-May. Back to positive organic growth in H2 2020.

- Sales down -6.2% organically.
- Near complete shutdown of activity over the 2-month lockdown in Europe in March and April.
- Faster than anticipated recovery with a significant rebound in paint sales, leading to strong organic growth in Q3 and Q4.
- Total growth of 5.7% in H2 2020.

EBITDA soared +34% (1), margin of 15.4% (up 460bps YoY).

- EBITDA stands at €96.9m⁽¹⁾.
- Benefiting from favorable customer, product and country mix, positive pricing dynamics, continued structural efforts on the cost base, further amplified by the rapid implementation of additional cost saving measures to deal with the exceptional COVID-19 situation and favorable raw materials costs.

Strong cash flow generation over the year, net debt reduction of €76m YoY.

Net leverage of 1.4x as of end of December 2020, halved vs 2019.

COVID-19 update

- Cromology is focusing its efforts on planning and managing operations in the context
 of the resumption of the pandemic in Europe as well as pursuing the execution of the
 transformation plans it has launched since 2019 and prioritizing sources of value
 creation.
- It also monitors closely its supply chain since the strong rebound of activity in Europe has led to strong raw materials demand resulting in tight material supplies and raw materials price increases.




⁽¹⁾ EBITDA including IFRS 16 impacts.

⁽²⁾ Net debt including IFRS 16 impacts.

Crisis Prevention Institute (CPI)





2020 FY Results | March 18, 2021

Revenue down -27.3% in 2020 due to the impact of the COVID-19 crisis and associated economic lockdowns and social distancing restrictions

- Since a low point in April (revenue down by c.55% in Q2) during full shutdowns, the activity progressively recovered thanks to CPI's timely enaction of virtual training programs
- In response to COVID-related restrictions on holding in-person training sessions, CPI introduced a new virtual program for the installed base of Certified Instructor ("CI") renewals, as well as a blended virtual / physical offering Initial Certification Program ("ICP") for new Cls
- The number of CIs training their colleagues, or "Learners", through CPI's virtual, elearning offering nearly doubled in 2020, continuing the shift to digital solutions

EBITDA margin of $40.9\%^{(1)}$,

- EBITDA down versus last year by c.35%⁽²⁾
- Earnings decline was partially offset by cost management initiatives implemented shortly after the lockdowns began

Covenant waiver negotiated with lenders until Q2 2021

- Leverage covenant waiver negotiated with lenders until the end of Q2 2021 in exchange for a minimum liquidity covenant set at \$7.5m (cash + available revolver)
- Net debt largely flat versus prior year due to continued cash flow generation through COVID

COVID-19 update

- Recent introduction of new programs, including virtual and blended options, verbal deescalation modules, and specialized renewal programs related to trauma and autism, are expected to help expand the Company's addressable market and support accelerated long-term growth
- A recent pick-up in demand has occurred, largely due to the ongoing vaccination effort in the US. However, the pace and timing of recovery remain difficult to predict
- CPI is returning to higher levels of forward bookings and fewer cancellations, more consistent with historical levels prior to COVID

EBITDA before goodwill allocation entries, management fees and non-recurring items. EBITDA is including IFRS 16 impacts; pre IFRS 16, 2020 EBITDA is \$25.1 million. 2019 figures post IFRS 16 not









No cash injected into our portfolio companies over the course of 2020

		ī		
	Net debt to EBITDA(1) (as of Dec. 31, 2019)	Net debt to EBITDA(1) (as of June 30, 2020)	Net debt to EBITDA(1) (as of December 31, 2020)	Net debt (as of December, 31, including IFRS 16)
Bureau Veritas	1.9x	2.0x	1.8x	€1,329m
Constantia Flexibles	2.0x	2.0x	1.8x	€362m
Stahl	1.9x	2.1x	1.6x	€245m
Cromology	2.7x	2.6x	0.5x	€138m
CPI	7.2x	10.0x	11.5x ⁽²⁾	\$338m

IHS Towers does not disclose its EBITDA

⁽¹⁾ As per credit documentation

⁽²⁾ In August 2020, CPI negotiated a leverage covenant waiver with its lenders through Q1 2021, with covenant testing resuming at the end of Q2, in exchange for a minimum liquidity covenant set at \$7.5 million (cash + available revolver)

Wendel financials


Full-Year 2020








Consolidated sales (in €m)



Net income from operations (in €m) (1)



(1) Net income before goodwill allocation entries and non-recurring items

— Net loss Group share of € 264.1 million

in millions of euros	2019	2020
Contribution from subsidiaries	589.5	430.7
Financial & operating expenses and taxes	(139.8)	(114.2)
Net income from operations (1)	449.7	316.5
Non-recurring income	442.2	(105.7)
Impairment and impact of goodwill allocation	(266.2)	(441.8) ←
Total net income (loss)	625.6	(231.0)
Net income, Group share	399.7	(264.1)

In 2019:

• €644m gain on sale of Allied Universal

In 2020:

Increase at portfolio companies and at Wendel level (full depreciation of Tsebo and €87.3m impairment for CPI)

⁽¹⁾ Net income before goodwill allocation entries and non-recurring items

Net Asset Value & Return to Shareholders







- Adjustments to NAV methodology implemented as of Dec. 31, 2020 No significant impact⁽¹⁾ on NAV as of December 31, 2020 (+0.3%)

2021 main updates concern unlisted assets

Primarily valued with peers multiples sample, reviewed annually



Transaction multiples and purchase offers may be used with application periods amended/ shortened in 2020



Valuation of a new acquisition, standstill for new investment through a time-weighted average of:

- (a) multiples at acquisition and
- (b) listed peer-group multiples for the first 18 months



Valuation modifiers for small/underperforming companies no longer retained



CPI: First valuation exercise at Dec. 31, 2020⁽²⁾:

Companies used share the following characteristics with CPI: recurring revenue derived from licenses, subscriptions, provision of training / certification offerings for customers required by regulation (i.e., governance, risk, compliance services)




Auditors check the consistent application of the methodology and our NAV calculation is benchmarked by an independent valuation expert

¹⁾ Impact of the annual review of samples included in the total impact of 0.3%.

CPI valued using market multiples for the first time at December 31, 2020, in compliance with the methodology prevailing at acquisition (acquisition value used for the NAV for the first 12 months following the acquisition).

— Net Asset Value bridge for 2020



As a reminder, Net Asset Value is a short-term valuation of the Group's assets. It does not take into account any control premiums, illiquidity or initial public offering discounts; similarly, aggregates used in the valuation of unlisted assets are not adjusted from potential additional costs arising from a stock market listing. According to the methodology, the samples of the listed are reviewed at least once a year when when required for relevance purpose.

W WENDEI

NAV of €159.1 as of December 31, 2020

(in millions of euros)			Dec. 31, 2020
Listed equity investments	Number of shares	Share price ⁽¹⁾	3,599
Bureau Veritas	160.8 million	€22.4	3,599
Investments in unlisted assets (2)			3,910
Other assets and liabilities of Wendel and	74		
Cash and marketable securities(4)	1,079		
Gross asset value	8,662		
Wendel bond debt			-1,548
Net asset value			7,114
Of which net debt			-468
Number of shares ⁽⁵⁾			44,719,119
Net asset value per share	€159.1		
Wendel's 20 days share price average			€97.9
Premium (discount) on NAV	-38.5%		


- (1) Last 20 trading days average as of December 31, 2020
- (2) Investments in non-publicly traded companies (Cromology, Stahl, IHS, Constantia Flexibles, Crisis Prevention Institute, indirect investments). As per previous NAV calculation IHS valuation was solely performed based on EBITDA which is at this stage the most relevant sub-total. As from December 20, CPI is valued with a market approach, as per methodology. Aggregates retained for the calculation exclude the impact of IFRS 16.
- (3) Of which 900,665 treasury shares as of December 31, 2020, and 908,950 treasury shares as of December 31, 2019
- (4) Cash position and financial assets of Wendel & holdings. As of December 31, 2020, this comprises € 0.9 bn of cash and cash equivalents and € 0.3 bn short term financial investment.


Assets and liabilities denominated in currencies other than the euro have been converted at exchange rates prevailing on the date of the NAV calculation.



Leverage – Net debt at low level and strong resilience of LTV


Improved LTV







Proposing a €2.90 per share dividend, up 3.6%



In euros per share, ordinary dividend

The 2011 ordinary dividend included an exceptional distribution of 1 Legrand share for every 50 Wendel shares held.



2024 Roadmap & Investment strategy

André François Poncet, Group CEO

David Darmon, Group Deputy CEO





LONG-TERM INVESTOR



- A refocused portfolio, poised for further redeployment

Beginning of 2018⁽¹⁾

13 companies in portfolio:

o/w 7 assets with equity valuations below €200m









OCY

13.1% LTV ratio

€1.7bn of Cash

8 offices

~€650 million

returned to shareholders

over the last 3 years 58% through dividends 42% through share buybacks

Leadership changes confirmed

ESG roadmap in place
Operating partners



Wendel as of end-2020

6 companies in portfolio:

Refocused on larger assets














6.2% LTV ratio

€1.1bn of Cash

3 offices

2021-2024 roadmap: active capital redeployment

Vision and Wendel's 2024 Ambition: Portfolio



Redeploy capital generally towards higher growth, ESG-friendly assets

Build portfolio of 7-10 companies with new investments of c. €150 to 500m. Wendel also contemplates equity investments in a few small growth opportunities

— Portfolio: our capital allocation strategy

Public and Private assets

- Balanced listed/unlisted portfolio
- Active and influential ownership in most cases
- Some exposure to Growth Equity/ Late-Stage VC

Sectors

- Resilient mainly /growing sectors with attractive long-term growth prospects
- Demonstrated resilience through economic cycles (and pandemic)
- Primarily industrials or business services including technology services and software, healthcare and industrial technology

Geographies

 Focus on Western Europe, particularly France, and North America (US and Canada) headquartered companies

Profile

- Market-leading businesses with pricing power and barriers to entry
- Avoid businesses with high cyclicality, capital intensity and limited differentiation
- Develop portfolio diversification, with limited macro correlation between companies

ESG

- Exclusion list
- Strong focus on ESG and compliance
- Companies which can use ESG as a value creation lever

— Portfolio: What we are looking for

Equity Investment

c.€150-500M over time per investment (smaller amounts for growth equity)

Company size

EV of €350-2,500M with minimum **EBITDA of €30-40m**, but opportunistically open to smaller tickets

Company type

Market or segment leaders with strong management teams

Investment type

Majority / control investments/ large minority investments



Growing, resilient with ESG potential value creation



Partner with like-minded management teams or co-investors with demonstrated track record



Value creation opportunity from organic and external growth and operational improvement



Robust cash flow generation and adequate leverage



Remaining opportunistic on situtations where Wendel can uniquely contribute and with long term perspectives

— Portfolio: Wendel Lab

Wendel Lab objectives...

- Develop an ecosystem of innovative partners to create value for our portfolio companies
- Build intelligence and expertise on disruptive technological and digital trends
- Source opportunities in Late-Stage VC and Growth direct equity and funds, for which our shareholders have no/limited direct access
- Diversify and support companies with higher growth profiles

Objectives:

~5-10% of NAV by 2024 Split between LP and direct investments

Today, c.\$125m already committed⁽¹⁾ in Wendel Lab

...to be realized through partnering with high quality players



(1) Of which €48m already invested as of December 2020

Wendel's 2024 target portfolio & returns

Listed Equity

Private Equity Buyout

Private Equity Growth Equity/ VC1

% of NAV

Balanced %

c. 5 to 10%

Target average annual return profile

Above c.7%

Above c.10%

~c. 10-15% (for funds) Above 25% in direct investments

1-Including funds

— Wendel's financing guidelines



Maintain available liquidity to enable Wendel to seize attractive opportunities (i.e., to safely make a €300M investment at most times)



Flexible financing structure that can withstand sudden, pronounced market shocks potentially resulting in capital needs at portfolio level



Pay a regular and growing dividend year on year



Retain investment grade rating profile

Key takeaways LONG-TERM INVESTOR







- Wendel is well positioned to seize further opportunities



Resilient overall portfolio stability with significant exposure to beneficiaries from ESG tailwinds



Moderate leverage at corporate & portfolio company levels



Roadmap to redeploy capital



Opportunity to embed ESG deeply into the firm, for competitive advantage



Tightened and agile organization and portfolio with strong focus, engaged leadership



Aiming at **paying a regular and growing dividend** year on year and perform **opportunistic share buyback**

Q&A session







Appendix 1







Weighted average cost of bond debt: **2.09%**

Average maturity:

4.5 years

€1.8 bn total liquidity


Moody's credit rating:

Baa2/stable

Since September 5, 2018

S&P credit rating:

BBB/stable Since January 25, 2019




2020 performance of Group's main unlisted companies


	Sales	Δ	Organic growth	EBITDA, Op. profit for BVI, EBIT for IHS ⁽¹⁾	Margin
Bureau Veritas	4,601.0	-9.8%	-6.0%	€615.0	13.4%
Constantia Flexibles	€1,505.3m	-1.9%	-0.4%	€189.4m	12.6%
Crisis Prevention Institute	\$63.8m	-27.3%	-27.3%	\$26.1	40.9%
IHS	\$1,403.1m	+14.0%	+16.3%	\$410.4m	29.2%
Stahl	€669.4m	-17.2%	-14.3%	€152.3m	22.7%
Cromology	€627.6m	-6.0%	-6.2%	€96.9m	15.4%




⁽¹⁾ EBIT and EBITDA before goodwill allocation entries, management fees, and non-recurring items. **Including IFRS 16 impacts** Financing documentation may include specific definitions of EBIT & EBITDA.

— Balanced exposure to geographies and sectors





GEOGRAPHIC EXPOSURE (1)



(1) Enterprise value exposure of Group companies, according to the breakdown of 2020 revenues.

Enterprise values are based on NAV calculations as of December 31, 2020

Appendix 2

Financial information as of Dec. 31, 2020







FY 2020 consolidated sales

in millions of euros	2019	2020	Δ	Organic Δ
Bureau Veritas	5,099.7	4,601.0	-9.8%	-6.0%
Constantia Flexibles	1,534.3	1,505.3	-1.9%	-0.4%
Cromology	667.8	627.6	-6.0%	-6.2%
Stahl	808.7	669.4	-17.2%	-14.3%
CPI	n.a.	56.0	n.a.	-24.9%
Consolidated sales	8,110.5	7,459.2	-8.0%	-5.8%

— FY 2020 sales of companies accounted for by the equity method

in millions of euros	2019	2020	Δ	Organic D
IHS	1,099.7	1,231.2	+12.0%	+16.3%

— IFRS 16 - Summary table of main aggregates before and after the application of IFRS 16

	Sal	es		ebitda (e	SIT for IHS) Net debt				
(in millions)	FY 2019	FY 2020	FY 2019 excluding IFRS 16	FY 2019 including IFRS 16	FY 2020 excluding IFRS 16	FY 2020 including IFRS 16	FY 2020 excluding IFRS 16	FY 2020 including IFRS 16	
IHS	\$1,231.1	\$1,403.1	\$276.0	\$284.1	\$395.7	\$410.4	\$1,617.8	\$1,932.5	
Stahl	€808.7	€669.4	€180.0	€183.0	€149.1	€152.3	€228.8	€245.0	
Constantia Flexibles	€1,534.3	€1,505.3	€176.8	€186.1	€174.8	€183.3 (1)	€330.8	€362.2	
Cromology	€667.8	€627.6	€41.5	€72.2	€63.6	€96.9	€27.6	€138.0	
CPI	\$87.7	\$63.8	\$38.9	n.a	\$25.1	\$26.1	\$333.1	\$337.8	

⁽¹⁾ Constantia Flexibles EBITDA excluding Covid 19 costs (considered as "recurring" by the AMF since October 2020) stood at €189,4 million (183,3 + 6,1).

— Net income from operations

In millions of euros	2019	2020
Bureau Veritas	477.7	302.8
Stahl	94.3	78.3
Constantia Flexibles	44.2	49.5
Cromology	-19.2	15.6
Tsebo	-9.2	-7.6
CPI	-	-2.6
Allied Universal (equity accounted)	58.5	-
Dividend from Saint-Gobain	4.1	-
IHS (equity accounted)	-60.9	-5.3
Total contribution from Group companies	589.5	430.7
of which Group share	233.6	191.5
Total operating expenses	-72.7	-64.8
Total financial expense	-67.2	-49.4
Net income from operations	449.7	316.5
of which Group share	85.4	77.3

— Consolidated income statement

In millions of euros	2019	2020
Net sales	8,110.5	7,459.2
Other income from operations	16.4	6.2
Operating expenses	-7,358.8	-6,940.3
Net gain (loss) on sale of assets	-3.4	-29.6
Asset impairment	-29.7	-170.5
Other income and expenses	-9.3	-24.6
Operating income	725.7	300.3
Income from cash and cash equivalents	4.6	9.1
Finance costs, gross	-249.5	-250.1
Finance costs, net	-244.5	-241.0
Other financial income and expense	-23.1	1.0
Tax expense	-249.1	-126.7
Net income (loss) from equity-method investments	-78.2	-63.5
Net income from continuing operations	130.3	129.8
Net income from discontinued operations and operations held for sale	495.3	-101.2
Net income	625.6	-231.0
Net income – non controlling interests	225.8	33.1
Net income – Group share	399.7	-264.1

In accordance with IFRS 5 "Non-current assets held for sale and discontinued operations," the contribution of Tsebo to 2019 net income has been reclassified to a single line in the income statement: "Net income from discontinued operations and operations held for sale. In 2020, Tsebo's contribution and the impact on income related to its disposal were recognized in the net income from discontinued operations or operations held for sale

— Consolidated balance sheet

In millions of euros	12/31/2020	12/31/2019	In millions of euros	12/31/2020	12/31/2019	
			Charre a gratted	170.0	170.7	
Goodwill	3, 488.6	4,112.0	Share capital Premiums	178.9 55.,3	178.7 53.3	
Intangible assets, net	1,692.3	1,769.0	Retained earnings & other reserves	2,033.6	1,791.5	
Property, plant & equipment, net	1,109.0	1,291.3	Net income for the year - Group share	-264.1	399.7	
Property, plant and equipment under operating leases	530.5	536.9		2,003.7	2,423.1	
Non-current financial assets	320.8	480.4	Non-controlling interests	1,283.8	1,392.5	
Pledged cash and cash equivalents	0.4	16.6	Total shareholders' equity	3,287.5	3,815.6	
Equity-method investments	225.2	294.0	Provisions	453.4	456.1	
Deferred tax assets	206.6	217.2	Financial debt	5,312.9	5,896.7	
Total non-current assets	7,573.4	8,717.5	Operating lease liabilities	448.4	458.2	
	.,	·	Other financial liabilities	283.9	454.9	
Accele of an auglions hald for only	0.2	55.3	Deferred tax liabilities	396.7	416.8	
Assets of operations held for sale	8.3	55.3	Total non-current liabilities	6,895.3	7,682.6	
Inventories	416.4	465.6	Liabilities of operations held for sale	-	15.4	
Trade receivables	1,375.3	1,697.4	Dec 11.	4.1	5.1	
Contract assets (net)	232.1	226.0	Provisions Financial debt	6.1 646.8	5.1 627.4	
Other current assets	327.5	354.5	Operating lease liabilities	134.4	132.8	
Current income tax	61.0	68.0	Other financial liabilities	179.5	112.5	
Other current financial assets	311.9	367.0	Trade payables	862.0	937.0	
	2,900.3	2,624.7	Other current liabilities	1,053.,0	1,091.9	
Cash and cash equivalents			Current income tax	141.6	155.6	
Total current assets	5 624.6	5,803.3	Total current liabilities	3,023.6	3,062.3	
Total assets	13,206.3	14,576.0	Total liabilities and shareholders' equity	13,206.3	14,576.0	

In accordance with IFRS 5 "Non-current assets held for sale and discontinued operations", the investment in the Tsebo group has been reclassified as "Assets and liabilities of discontinued operations or held for sale" at January 1, 2020 before exiting the scope at the end of December 2020. See Notes 3 "Changes in scope of consolidation" and 18 "Discontinued operations and operations held for sale".



— Conversion from accounting presentation to economic presentation

(in millions of euros)	Bureau Veritas	Constantia Flexibles	Cromology	Stahl	Tsebo	СРІ	Equity- method investments IHS	Wendel holding companies	Group total
Net income from operations									
Net sales	4 601,0	1 505,3	627,6	669,4	-	56,0			7 459,2
EBITDA (1)	N/A	183,3	96,9	152,3	-	22,9			
Adjusted operating income (1)	615,0	79,4	44,8	124,4	-1,4	15,8			878,0
Other recurring operating items		2,0	1,3	1,5	0,7	0,4			
Operating income	615,0	81,4	46,0	125,9	-0,7	16,2		-63,7	820,2
Finance costs, net	-105,6	-16,9	-18,3	-18,2	-	-25,7		-33,5	-218,2
Other financial income and expense	-32,2	-3,6	-0,3	-1,5	-0,7	-0,5		-15,9	-54,7
Tax expense	-174,7	-11,4	-11,6	-27,9	-	7,4		-1,1	-219,3
Share in net income of equity-method investments	0,1	0,0	-0,2	-	-	-	-5,3	-	-5,4
Net income from discontinued operations and operations held for sale	-	-	-	-	-6,2	-		-	-6,2
Net income from operations	302,8	49,5	15,6	78,3	-7,6	-2,6	-5,3	-114,2	316,4
Net income from operations – non-controlling interests	200,7	18,3	0,7	25,1	-5,5	-0,1	-0,0	-0,1	239,2
Net income from operations – Group share	102,1	31,2	14,9	53,2	-2,1	-2,5	-5,3	-114,2	77,3
Non-recurring income									-
Operating income	-207,7	-126,0	-8,1	-23,6	-	-135,1		-18,6	⁽²⁾ -519,2
Net financial expense(income)	-	-2,6	-	26,7 (4	.) _	-		8,6	
Tax expense	43,9	23,7	0,5	-0,5	-	24,6			92,3
Share in net income of equity-method investments	-	-0,1	-	-	-	-	-58,0 (5) -	-58,1
Net income from discontinued operations and operations held for sale	-	-	-	1,0	-95,1 (6) _		-1,0	-95,1
Non-recurring net income	-163,8	-105,0	-7,6	3,6	-95,1	-110,5	-58,0	-11,1	-547,4
of which:									
- Non-recurring items	-33,2	-21,6	-7,2	19,1	-	-1,7	-52,8	-11,1	-108,5
- Impact of goodwill allocation	-104,0	-29,6	-0,3	-15,5	-	-21,4		-	-171,0
- Asset impairment	-26,6	-53,9	-	-	-95,1	-87,3	-5,2	-	-268,0
Non-recurring net income – non-controlling interests	-106,6	-40,6	-0,4	1,2	-55,2	-4,3	-0,2	-0,0	-206,1
Non-recurring net income – Group share	-57,2	-64,5	-7,2	2,5	-39,9	-106,1	-57,9	-11,1	-341,4
Consolidated net income	138,9	-55,5	8,0	81,9	-102,7	-113,0	-63,3	-125,3	-231,0
Consolidated net income – non-controlling interests	94,1	-22,3	0,4	26,3	-60,7	-4,4	-0,2	-0,1	33,1
Consolidated net income – Group share	44,8	-33,2	7,7	55,6	-42,0	-108,6	-63,1	-125,2	-264,1

^{1.} Before the impact of goodwill allocation, non-recurring items and management fees.

^{2.} This item includes the net income from the unwinding of the guarantee relating to the financing of an investor of Tsebo (see Note 3 of financial statements "Changes in scope of consolidation") and the impact of to the co-investment mechanisms for -€20 million.

^{3.} This item includes the foreign exchange impact for the period for +€3.2 million and the change in the fair value of Wendel Lab's financial assets for +€3.1 million.

^{4.} This item includes the foreign exchange impact for the period of +€31.9 million.

^{5.} This item includes the exchange rate impact for the period of -€71.4 million and the fair value of derivatives for +€20.4 million.

^{6.} See Note 3 of financial statements "Changes in scope of consolidation" on Tsebo.

Financial agenda







Financial agenda

04.28.2021

Q1 2021 Trading update / Publication of NAV as of March 31, 2021 (pre-market release)

06.29.2021

Annual General Meeting

07.29.2021

H1 2021 results / Publication of NAV as of June 30, 2021, and condensed Half-Year consolidated financial statements (pre-market release)

10.28.2021

Q3 2021 Trading update / Presentation of NAV as of September 30, 2021 (pre-market release)

12.02.2021

2021 Investor Day / Meeting to take place in the morning

Disclaimer

- This document has been prepared by Wendel S.E. ("Wendel") solely for use at the 2020 annual results presentation, to be held on March 18, 2021. This document must be treated confidentially by attendees at such presentation and may not be reproduced or redistributed to any other person.
- No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein and Wendel expressly disclaims any liability relating thereto. Wendel is under no obligation to keep current the information contained in this presentation and any opinions expressed in this representation are subject to change without notice.
- This document may include forward-looking statements. These forward-looking statements relate to Wendel's and its affiliates' future prospects, developments and business strategies and are based on analyses of estimates of amounts not yet determinable. By their nature, forward-looking statements involve risks and uncertainties. Wendel cautions you that forward-looking statements are not guarantees of future performance and that its actual financial condition, actual results of operations and cash flows and the development of the industries in which Wendel or its affiliates operate may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. Wendel does not undertake any obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise after the date of this document, unless required by law or any applicable regulation.
- No liability is accepted for the consequences of any reliance upon any statement of any kind (including statements of fact or opinion) contained herein.
- This presentation includes only summary information and must be read in conjunction with Wendel's Financial Reports, which may be obtained on the website of Wendel (www.wendelgroup.com) and the Universal Registration Document submitted on April 16, 2020 to the AMF under the number D. 20-0296. You are invited to take carefully into consideration the risk factors described in these documents.
- No information provided on this document constitutes, or should be used or considered as, an offer to sell or a solicitation of any offer to buy the securities or services of Wendel or any other issuer in any jurisdiction whatsoever. Wendel securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
- By attending this presentation and/or accepting this document you agree to be bound by the foregoing limitations.

